Login

Switch On Your HIV Smarts.

Author Archives: Liz Highleyman

PrEP use since 2012 is up, but uptake falls short of need

PrEP use since 2012 is up, but uptake falls short of need

, by Liz Highleyman

1.45 million Americans may be at substantial risk for HIV infection, but only 8% are taking PrEP. Women, people of color, and southern regions are underrepresented. Read More

CROI 2018: A roundup of the most exciting PrEP news & research

CROI 2018: A roundup of the most exciting PrEP news & research

, by Liz Highleyman

Liz Highleyman summarizes the PrEP and HIV prevention research presented recently at the domestic HIV conference, CROI, including a new possible PrEP drug, real world PrEP effectiveness, and more. Read More

HIV remission: more clues, but still many questions

HIV remission: more clues, but still many questions

, by Liz Highleyman

Very early HIV treatment does not cure HIV, but can lead to HIV remission in some people, new studies presented at IAS 2017 show. Read More

Surprising price break for newly-approved hepatitis C drug

Surprising price break for newly-approved hepatitis C drug

, by Liz Highleyman

Two new hepatitis C cure drugs, Mavyret and Vosevi, have been approved by the FDA—offering a shorter course of treatment, for a lower cost. Read More

Long-acting antiretrovirals for HIV treatment and PrEP

Long-acting antiretrovirals for HIV treatment and PrEP

, by Liz Highleyman

At the recent IAS 2017 conference, we got good news about the safety and efficacy of a long-acting antiretroviral injection and a drug in a new class of medications. Read More